Clinical Trial Update: An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating SR58611A for generalized anxiety disorder in elderly patients has been terminated in an eight-week trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• SR58611A

Snippet

Sponsor: Sanofi | Conditions: Anxiety Disorders | Phase 3 | Status: TERMINATED